Febit Holding GMBH has acquired a European patent for a microarray-based nucleic-acid extraction procedure.
The new patent refers to a technology that has already been used for selecting and enriching DNA for re-sequencing purposes.
This technology enhances the efficiency of high-throughput re-sequencing and renders it suitable for a spectrum of applications in medical and biological studies.
Targeted re-sequencing of medically relevant genomic loci enables new approaches to research normal cellular functions and pathological changes observed in major diseases such as cancer and Alzheimer's disease.
The results of these investigations will allow the development of novel diagnostic tests and enhance specificity of drug therapies.
